Johnson & Johnson at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 05:45PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside discussion today with Joaquin Duato, Chairman and CEO of J&J. So Joaquin, Happy New Year. Great speaking with you today.

Questions and Answers:

Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst

I thought it might be a good way to start the conversation just with some of your reflections on 2023. It was obviously a very busy, very productive year for the company. So why don't we kick off there, and we can jump on some topics from there?

Joaquin Duato - Johnson & Johnson - CEO & Chairman

Thank you, Chris, and good morning, everybody. Yes, 2023 was a very productive year for Johnson & Johnson. We had our Enterprise Business Review Day back in December. And it was a very symbolic moment for us because for the first time, we presented what is the new Johnson & Johnson,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot